Phae Blue is a true insider’s gem—discover a stay filled with local flavour, thoughtful design, and serious food credentials.

Blackstone Life Sciences and Anthos Therapeutics, Inc., a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of cardiometabolic diseases ...

Swiss pharmaceutical giant Novartis announced on Tuesday the purchase of Cambridge-based biopharma firm Anthos Therapeutics for $925 million upfront. The deal, which is expected to close in the ...

Novartis is expanding its prospects in cardiometabolic disease by striking a deal to acquire Anthos Therapeutics, a company in pivotal testing with a blood clot-preventing drug that could offer ...

Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's drug development unit, for up to $3.1 billion, to boost its ...

Novartis NOVN-0.13%decrease; red down pointing triangle agreed to acquire Blackstone Life Sciences’ Anthos Therapeutics for up to $3.08 billion to boost its cardiovascular-drug pipeline.

Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, Novartis has struck a deal to buy Anthos for $925 million upfront to add the ...

Novartis to acquire Anthos Therapeutics for up to $3.1 billion View all comments (0) 0 Latest comments Post Comment Guidelines Trade With A Regulated Broker Indices Commodities Bonds Stocks US 30 ...

(Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's drug development unit, for up to $3.1 billion, to boost its ...

Feb 11 (Reuters) - Swiss pharmaceutical giant Novartis (NOVN.S), opens new tab has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's (BX.N), opens new tab drug ...